➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Baxter
Express Scripts
McKesson
Dow

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PEGAPTANIB SODIUM

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Pegaptanib Sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00040313 ↗ Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula Completed Eyetech Pharmaceuticals Phase 2 2002-10-01 The purpose of the study is to determine whether pegaptanib sodium (Macugen) is safe and effective in slowing the leakage of fluid within the retina and thereby stabilizing or improving vision when compared to placebo injections. A total of 176 patients will be enrolled
NCT00087763 ↗ Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD) Completed Pfizer Phase 2 2004-03-01 The purpose of this study is to determine if Macugen™ reduces foveal thickness and improves vision in patients with wet AMD.
NCT00087763 ↗ Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD) Completed Eyetech Pharmaceuticals Phase 2 2004-03-01 The purpose of this study is to determine if Macugen™ reduces foveal thickness and improves vision in patients with wet AMD.
NCT00088192 ↗ Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD) Completed Pfizer N/A 2004-07-01 To provide Pegaptanib sodium injection to patients with subfoveal choroidal neovascularization (CNV) secondary to AMD, who are unable to participate in any of the Sponsor’s other clinical studies with this drug for AMD, until such time as the patient’s lesion is considered to have resolved or stabilized in the opinion of the treating ophthalmologist, or product becomes commercially available.
NCT00088192 ↗ Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD) Completed Eyetech Pharmaceuticals N/A 2004-07-01 To provide Pegaptanib sodium injection to patients with subfoveal choroidal neovascularization (CNV) secondary to AMD, who are unable to participate in any of the Sponsor’s other clinical studies with this drug for AMD, until such time as the patient’s lesion is considered to have resolved or stabilized in the opinion of the treating ophthalmologist, or product becomes commercially available.
NCT00088283 ↗ Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) Completed Pfizer Phase 2 2004-05-01 Eyetech Pharmaceuticals Inc. and Pfizer, Inc. are studying an investigational drug, MacugenTM, for the possible treatment of CRVO. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). This investigational drug may slow the growth of abnormal blood vessels in the eye and may reduce tissue swelling in the eye. The purpose of this study is to compare the safety and efficacy of a Macugen™ injection to a “pretend” injection. In addition, the purpose of this study is to measure the action of the study drug in the body over a period of time and to check for the presence of the study drug in your blood (called pharmacokinetics or PK). This study will involve approximately 90 people. People who decide to participate will have an equal chance (1 in 3) to receive one of three study injections, two of which are Macugen™ and one of which is a “pretend” injection.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Pegaptanib Sodium

Condition Name

Condition Name for Pegaptanib Sodium
Intervention Trials
Macular Degeneration 8
Diabetic Macular Edema 5
Age-Related Macular Degeneration 5
Retinopathy of Prematurity 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Pegaptanib Sodium
Intervention Trials
Macular Degeneration 16
Macular Edema 11
Edema 7
Retinal Diseases 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Pegaptanib Sodium

Trials by Country

Trials by Country for Pegaptanib Sodium
Location Trials
United States 91
Japan 38
France 6
Canada 4
Spain 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Pegaptanib Sodium
Location Trials
Texas 9
California 7
Florida 6
Pennsylvania 5
Michigan 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Pegaptanib Sodium

Clinical Trial Phase

Clinical Trial Phase for Pegaptanib Sodium
Clinical Trial Phase Trials
Phase 4 8
Phase 3 4
Phase 2/Phase 3 3
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Pegaptanib Sodium
Clinical Trial Phase Trials
Completed 19
Terminated 6
Withdrawn 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Pegaptanib Sodium

Sponsor Name

Sponsor Name for Pegaptanib Sodium
Sponsor Trials
Pfizer 19
Eyetech Pharmaceuticals 11
Johns Hopkins University 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Pegaptanib Sodium
Sponsor Trials
Industry 32
Other 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Colorcon
McKesson
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.